Blau Farmacêutica S.A (BLAU3)
Sao Paulo Exchange · Brazil · prices in BRL · close of 16 Oct 2026
Key indicators
| Last close | BRL 12.21 |
|---|---|
| 52-week range | 8.28 – 14.28 |
| Return, 1 month / 3 months | +15.7% / +34.0% |
| Return, 1 year / 3 years | +35.5% / +14.7% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 51.9% |
| Worst drawdown (1 year) | -39.0% |
| Average daily value traded | 2.90M BRL |
| Dividend yield | 8.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Blau Farmacêutica is a Brazilian pharmaceutical company that develops, manufactures and markets medicines for hospitals and specialised care. Its products cover areas such as oncology, nephrology, haematology and hospital treatments, supplied to hospitals, clinics and healthcare providers in Brazil and other Latin American markets. The company is based in São Paulo state and runs its own manufacturing facilities, combining branded medicines with products made under partnership arrangements for medical institutions.
Blau Farmacêutica S.A trades under the code BLAU3 on the Sao Paulo Exchange in Brazil, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Blau Farmacêutica S.A (BLAU3) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 12.21 on 16 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 324 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 35.5% and over the last three months it rose 34.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 20.7% | ||
| From 52-week high | -10.8% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 34.0% | ||
| 6-month return | 6.1% | ||
| 12-month return, skipping the last month | 17.1% | ||
| Stability (higher is calmer) | 33 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 51.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.0% | ||
| Liquidity | 86 · Strong | Trades actively. | |
| Average daily value traded | 2.90M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 76 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 8.4% | ||
| Years with dividends | 6 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | +15.7% |
| 3 months | +34.0% |
| 6 months | +6.1% |
| 1 year | +35.5% |
| 3 years | +14.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 10.13 / 10.12 |
|---|---|
| Golden / death cross (60 days) | Golden, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.48 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 Jun 2026 | BRL 0.0773 |
| 23 Mar 2026 | BRL 0.0758 |
| 18 Dec 2025 | BRL 0.7317 |
| 4 Dec 2025 | BRL 0.1463 |
| 23 Sep 2025 | BRL 0.1244 |
| 21 Mar 2025 | BRL 0.3292 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.